Communiqués Rigel Pharmaceuticals, Inc.

Actions

RIGL

US7665597024

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 25/09/2026			Varia. 5j.	Varia. 1 janv.
48,18 ^USD	+0,61%		+3,30%	+12,49%

13/08	Rigel Pharmaceuticals annonce la disponibilité de VEPPANU (vepdegestrant) pour les patientes atteintes d'un cancer du sein avancé ou métastatique ER+/HER2- présentant une mutation ESR1	CI
13/08	Rigel annonce la disponibilité du Veppanu, son traitement contre le cancer du sein, aux États-Unis et à Porto Rico	MT

Communiqués

02/09	Rigel to Participate in Upcoming September Investor Conferences	PR
13/08	Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer	PR
05/08	Rigel Pharmaceuticals : Quarterly Report for Quarter Ending JUNE 30, 2026 (Form 10-Q)	PU
04/08	Rigel: Q2 Earnings Snapshot	AQ
04/08	Rigel Reports Second Quarter 2026 Financial Results	PR
28/07	Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results	PR
07/07	Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	PR
01/07	Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer	PR
16/06	Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)	PR
27/05	Rigel to Present at the Jefferies Global Healthcare Conference	PR
21/05	Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress	PR
14/05	Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference	PR
12/05	Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer	PR
06/05	Rigel Pharmaceuticals : Quarterly Report for Quarter Ending MARCH 31, 2026 (Form 10-Q)	PU
06/05	Rigel Pharmaceuticals : Earnings Presentation Q1 2026	PU
06/05	Rigel Pharmaceuticals : May 2026 Corporate Presentation	PU
05/05	Rigel: Q1 Earnings Snapshot	AQ
05/05	Rigel Reports First Quarter 2026 Financial Results	PR
28/04	Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results	PR
07/04	Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	PR
31/03	Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology	PR
10/03	Rigel Pharmaceuticals : March 2026 Corporate Presentation	PU
04/03	Rigel Pharmaceuticals : March 2026	PU
03/03	Rigel: Q4 Earnings Snapshot	AQ
03/03	Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update	PR